BACKGROUND This study is a pre-registration trial of generic duloxetine that was approved by the China Food and Drug Administration (approval number: 2006L01603). AIMS Compare the treatment efficacy and safety of generic duloxetine to that of paroxetine in patients with major depressive disorders (MDD). METHODS This was a double-dummy, double-blind, multicenter, positive drug (paroxetine), ...

OBJECTIVE To evaluate the efficacy and safety of duloxetine hydrochloride in the treatment of patients affected by chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS). METHODS Thirty-eight CP/CPPS patients completed the National Institutes of Health Chronic Prostatitis Symptom Index (NIH-CPSI) and International Index of Erectile Function-Erectile Function-5 (IIEF-5) questionnaires, uro...

History of introduction duloxetine in medical practice, mechanism action and using concervative treatment women men with stress urinary incontinence are shown. Modern structure external urethral sphincter was shown increasing tone under influence.
 Duloxetine recommended by International Continent Society for initial but this drug gives only improvement urine continence quality life side e...

BACKGROUND Duloxetine hydrochloride is approved for the treatment or management of major depressive disorder, generalized anxiety disorder, diabetic peripheral neuropathic pain, chronic musculoskeletal pain, and fibromyalgia in the United States. These conditions affect millions of women, including those of childbearing potential. In pregnancy, pharmacological treatment is justified only if the...

background: treating inflammatory bowel disease (ibd) with antidepressants might be of utility to improve patient’s condition. the aim of this study was to assess the efficacy of duloxetine on depression, anxiety, severity of symptoms, and quality of life (qol) in ibd patients. materials and methods: in a randomized, double-blind, controlled clinical trial on  2013-2014, in alzahra hospital (is...

This was a 12-week, randomized, double-blind, placebo-controlled trial to assess the efficacy and safety of duloxetine, a selective serotonin and norepinephrine reuptake inhibitor, in 354 female patients with primary fibromyalgia, with or without current major depressive disorder. Patients (90% Caucasian; mean age, 49.6 years; 26% with current major depressive disorder) received duloxetine 60 m...